A Phase I, randomized controlled clinical trial to study the reactogenicity and immunogenicity of a new split influenza vaccine derived from a non-tumorigenic cell line.

Developments in biological standardization

Volumn 98, Issue , 1999, Pages

  Percheson, P B ^a   Trepanier P ^a   Dugre R ^a   Mabrouk, T ^a  

^a BioChem Vaccines Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; ARTICLE; CELL LINE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; IMMUNOLOGY; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MALE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; VIRUS CULTURE;

ADOLESCENT; ADULT; CELL LINE; CONSUMER PRODUCT SAFETY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; MALE; MIDDLE AGED; VIRUS CULTIVATION;

EID: 17044452705     PISSN: 03015149     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)